Laurus Labs

Laurus Labs, the Hyderabad-based pharmaceutical company, has reported impressive financial results for the fourth quarter of FY25, with net profit soaring three-fold to Rs 234 crore. This marks a significant increase from Rs 76 crore in the same quarter of the previous fiscal year. The company's revenue also saw a rise, reaching Rs 1,720 crore compared to Rs 1,440 crore in FY24. For the entire fiscal year, Laurus Labs reported a profit of Rs 358 crore, up from Rs 161 crore in FY24.

Laurus Labs touched 52-week high in today's session but the stock ended almost flat. Laurus Labs will be in focus as the company is about to announce its quarterly numbers. The stock’s climb to a new 52-week high of Rs 659.95 on April 23 is more than a technical milestone—it reflects growing investor faith in the company’s strategic pivot toward high-value synthesis and finished dosage businesses. Despite divergent views among market analysts, Laurus Labs has posted one of the most compelling stories of operational excellence and future promise.